HUBB vs LEGN vs ETN vs FATE vs EMR

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Hubbell Incorporated (HUBB) offers the better valuation at 29. 8x trailing P/E (24. 9x forward), making it the more compelling value choice. Analysts rate Legend Biotech Corporation (LEGN) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hubbell Incorporated (HUBB) is the cheapest at 29.

8x versus Eaton Corporation plc at 38. 4x. On forward P/E, Emerson Electric Co. is actually cheaper at 21. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Hubbell Incorporated wins at 1. 20x versus Emerson Electric Co. 's 4. 80x — a reasonable growth-adjusted valuation.

Over the past 5 years, Eaton Corporation plc (ETN) delivered a total return of +185.

3%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: ETN returned +614. 3% versus LEGN's -24. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.

76β versus Fate Therapeutics, Inc. 's 1. 99β — meaning FATE is approximately 163% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 68% for Emerson Electric Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Fate Therapeutics, Inc. grew EPS 29. 9% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hubbell Incorporated (HUBB) is the more profitable company, earning 15.

2% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HUBB leads at 20. 8% versus -22. 2% for FATE. At the gross margin level — before operating expenses — LEGN leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Hubbell Incorporated (HUBB) is the more undervalued stock at a PEG of 1. 20x versus Emerson Electric Co. 's 4. 80x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Emerson Electric Co. (EMR) trades at 21. 7x forward P/E versus 116. 2x for Legend Biotech Corporation — 94. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 1552. 7% to $39. 50.

In this comparison, EMR (1.

5% yield), HUBB (1. 1% yield), ETN (1. 0% yield) pay a dividend. LEGN, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eaton Corporation plc (ETN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

0% yield, +614. 3% 10Y return). Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ETN: +614. 3%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HUBB (Industrials) and LEGN (Healthcare) and ETN (Industrials) and FATE (Healthcare) and EMR (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HUBB is a mid-cap quality compounder stock; LEGN is a small-cap high-growth stock; ETN is a mid-cap quality compounder stock; FATE is a small-cap quality compounder stock; EMR is a mid-cap quality compounder stock. HUBB, ETN, EMR pay a dividend while LEGN, FATE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.